Compare NNY & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNY | MCRB |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.8M | 162.7M |
| IPO Year | N/A | 2015 |
| Metric | NNY | MCRB |
|---|---|---|
| Price | $8.45 | $16.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 50.9K | ★ 323.1K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $27.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.58 | $6.53 |
| 52 Week High | $8.87 | $29.98 |
| Indicator | NNY | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 47.60 |
| Support Level | $8.41 | $16.50 |
| Resistance Level | $8.59 | $17.52 |
| Average True Range (ATR) | 0.12 | 1.14 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 61.54 | 26.56 |
Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.